About Savara Pharma
Savara Pharma is a company based in Austin (United States) founded in 2008.. Savara Pharma has raised $67.82 million across 14 funding rounds from investors including Texas.gov, Cystic Fibrosis Foundation and Keiretsu Forum. The company has 59 employees as of December 31, 2024. Savara Pharma has completed 1 acquisition, including Serendex Pharmaceuticals. Savara Pharma offers products and services including MOLBREEVI. Savara Pharma operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Austin, United States
- Employees 59 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Savara, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-95.88 M-75.29as on Dec 31, 2024
-
EBITDA
$-102.92 M-72.02as on Dec 31, 2024
-
Total Equity Funding
$67.82 M (USD)
in 14 rounds
-
Latest Funding Round
$27 M (USD), Post-IPO
Dec 20, 2019
-
Investors
Texas.gov
& 10 more
-
Employee Count
59
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Savara Pharma
Savara Pharma is a publicly listed company on the NASDAQ with ticker symbol SVRA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Savara Pharma
Savara Pharma offers a comprehensive portfolio of products and services, including MOLBREEVI. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhaled recombinant GM-CSF for treating autoimmune pulmonary alveolar proteinosis.
Unlock access to complete
Unlock access to complete
Funding Insights of Savara Pharma
Savara Pharma has successfully raised a total of $67.82M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $27 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 14
- Last Round Post-IPO — $27.0M
-
First Round
First Round
(08 Jun 2009)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2019 | Amount | Post-IPO - Savara Pharma | Valuation |
investors |
|
| Dec, 2017 | Amount | Post-IPO - Savara Pharma | Valuation |
investors |
|
| Feb, 2016 | Amount | Series C - Savara Pharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Savara Pharma
Savara Pharma has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Texas.gov, Cystic Fibrosis Foundation and Keiretsu Forum. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on the biotechnology sector
|
Founded Year | Domain | Location | |
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Founded Year | Domain | Location | |
|
Accredited investors are networked for private equity funding opportunities.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Savara Pharma
Savara Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Serendex Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Pharmaceutical drug development company focusing on respiratory conditions
|
2008 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Savara Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Savara Pharma Comparisons
Competitors of Savara Pharma
Savara Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Savara Pharma
Frequently Asked Questions about Savara Pharma
When was Savara Pharma founded?
Savara Pharma was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Where is Savara Pharma located?
Savara Pharma is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Who is the current CEO of Savara Pharma?
Matt Pauls is the current CEO of Savara Pharma.
Is Savara Pharma a funded company?
Savara Pharma is a funded company, having raised a total of $67.82M across 14 funding rounds to date. The company's 1st funding round was a Series C of $20.67M, raised on Jun 08, 2009.
How many employees does Savara Pharma have?
As of Dec 31, 2024, the latest employee count at Savara Pharma is 59.
What does Savara Pharma do?
Savara Pharma was founded in 2008 and is headquartered in Austin, United States. Operations are centered in the biotechnology sector, where therapeutics for rare respiratory diseases are developed. The lead product, molgramostim nebulizer solution, is formulated as an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) targeted at autoimmune pulmonary alveolar proteinosis (aPAP). Focus remains on advancing treatments for underserved pulmonary conditions.
Who are the top competitors of Savara Pharma?
Savara Pharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does Savara Pharma offer?
Savara Pharma offers MOLBREEVI.
Is Savara Pharma publicly traded?
Yes, Savara Pharma is publicly traded on NASDAQ under the ticker symbol SVRA.
How many acquisitions has Savara Pharma made?
Savara Pharma has made 1 acquisition, including Serendex Pharmaceuticals.
Who are Savara Pharma's investors?
Savara Pharma has 11 investors. Key investors include Texas.gov, Cystic Fibrosis Foundation, Keiretsu Forum, EcoR1, and Logos Capital.
What is Savara Pharma's ticker symbol?
The ticker symbol of Savara Pharma is SVRA on NASDAQ.